A Simple Once-a-Week Shot to Lose Weight
It’s never been so simple and available. With GLP-1 medications like Semaglutide and Tirzepatide, achieving sustainable weight loss is now more accessible than ever.
Semaglutide is injected once a week, on the same day each week. It can be administered at any time of the day, regardless of meals.
You’ll typically begin with a low dose and gradually increase it every four weeks until reaching the target maintenance dose of 2.4 mg once weekly. However, if you cannot tolerate 2.4 mg, your provider may adjust your maintenance dose to 1.7 mg per week.
This gradual titration schedule is designed to manage potential side effects. If you experience difficulty tolerating the medication, your healthcare provider may adjust your dosage or recommend stopping the treatment.
Tirzepatide is administered subcutaneously once a week, usually starting at a dose of 2.5 mg and potentially increasing up to a maximum of 15 mg.
Subcutaneous administration involves injecting the medication into the layer of tissue directly beneath the skin, allowing for gradual absorption into the bloodstream. These injections are typically given at an angle into fatty areas of the body, such as the abdomen, thighs, or upper arms.
Brand-name medications like Zepbound and Mounjaro are available in convenient pre-measured auto-injector pens, making them user-friendly.
Most patients maintain therapeutic dosages of 5 mg or 7.5 mg weekly, though higher concentrations are also available. An initial dosing schedule helps establish the titration protocol to achieve the maintenance dosage.
Recent studies suggest that tirzepatide outperforms semaglutide in several key areas. The dual mechanism of action of tirzepatide, targeting both GLP-1 and GIP receptors, may make it a more effective option for individuals needing weight management alongside glucose control.
A study published in the New England Journal of Medicine found that tirzepatide at all doses was not only noninferior but also superior to semaglutide. The study reported greater reductions in body weight with tirzepatide compared to semaglutide. Although further research is needed, tirzepatide’s effectiveness appears promising.
The side effect profiles of both medications are generally similar, with the most frequent adverse events being gastrointestinal-related. However, tirzepatide may have a higher incidence of severe side effects at higher doses compared to semaglutide.
Ultimately, the choice between the two medications depends on individual patient response and personal preference. (Take a look at this study in the New England Journal of Medicine.)
Before starting any type of treatment, always consult a trained medical professional. Certain treatments, medications, or therapies may carry risks or interact with existing health conditions or medications. Consulting with a medical professional ensures that the chosen treatment is safe and appropriate for you.
Metabolic health is not one-size-fits-all. A reputable company and its staff can tailor treatment plans to your unique needs, taking into account your individual medical profile and history.